Published in J Antimicrob Chemother on April 21, 2009
Evolution of MRSA during hospital transmission and intercontinental spread. Science (2010) 13.34
Toward new therapeutics for skin and soft tissue infections: propargyl-linked antifolates are potent inhibitors of MRSA and Streptococcus pyogenes. PLoS One (2012) 1.16
Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance. Antimicrob Agents Chemother (2012) 0.99
In vitro studies indicate a high resistance potential for the lantibiotic nisin in Staphylococcus aureus and define a genetic basis for nisin resistance. Antimicrob Agents Chemother (2011) 0.95
Protein design algorithms predict viable resistance to an experimental antifolate. Proc Natl Acad Sci U S A (2014) 0.90
Winning the arms race by improving drug discovery against mutating targets. ACS Chem Biol (2011) 0.81
Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance. Antimicrob Agents Chemother (2010) 0.76
Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model. Antimicrob Agents Chemother (2009) 0.75
Determinants of Genetic Diversity of Spontaneous Drug Resistance in Bacteria. Genetics (2016) 0.75
Single-molecule sequencing reveals the molecular basis of multidrug-resistance in ST772 methicillin-resistant Staphylococcus aureus. BMC Genomics (2015) 0.75
Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet (2008) 2.88
Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol (2011) 2.68
The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden. J Antimicrob Chemother (2003) 1.72
Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents. Antimicrob Agents Chemother (2005) 1.71
Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J Antimicrob Chemother (2002) 1.57
A fusidic acid-resistant epidemic strain of Staphylococcus aureus carries the fusB determinant, whereas fusA mutations are prevalent in other resistant isolates. Antimicrob Agents Chemother (2004) 1.52
In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother (2005) 1.47
Molecular basis of fusB-mediated resistance to fusidic acid in Staphylococcus aureus. Mol Microbiol (2006) 1.44
The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood (2013) 1.42
Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques. Antimicrob Agents Chemother (2004) 1.39
Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob Agents Chemother (2008) 1.35
pH as a trigger of peptide beta-sheet self-assembly and reversible switching between nematic and isotropic phases. J Am Chem Soc (2003) 1.32
Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques. Expert Opin Investig Drugs (2004) 1.31
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2008) 1.25
Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol (2009) 1.25
Comparison of assays for detection of agents causing membrane damage in Staphylococcus aureus. J Antimicrob Chemother (2004) 1.22
Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low. J Antimicrob Chemother (2002) 1.20
Anti-staphylococcal activity and mode of action of clofazimine. J Antimicrob Chemother (2004) 1.17
Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. J Virol (2009) 1.10
Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections. J Antimicrob Chemother (2004) 1.08
The target of daptomycin is absent from Escherichia coli and other gram-negative pathogens. Antimicrob Agents Chemother (2012) 1.06
XF-70 and XF-73, novel antibacterial agents active against slow-growing and non-dividing cultures of Staphylococcus aureus including biofilms. J Antimicrob Chemother (2010) 1.04
Structure-based discovery of antibacterial drugs. Nat Rev Microbiol (2010) 1.04
Increased mutability of Staphylococci in biofilms as a consequence of oxidative stress. PLoS One (2012) 1.03
The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol (2009) 1.01
The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett (2005) 1.00
Mechanisms of the post-antibiotic effects induced by rifampicin and gentamicin in Escherichia coli. J Antimicrob Chemother (2006) 0.99
Assay platform for clinically relevant metallo-β-lactamases. J Med Chem (2013) 0.99
Functional and biochemical analysis of the Chlamydia trachomatis ligase MurE. J Bacteriol (2009) 0.98
Biological properties of novel antistaphylococcal quinoline-indole agents. Antimicrob Agents Chemother (2003) 0.97
Functional and biochemical analysis of Chlamydia trachomatis MurC, an enzyme displaying UDP-N-acetylmuramate:amino acid ligase activity. J Bacteriol (2003) 0.97
Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis (2011) 0.97
Biochemical characterisation of the chlamydial MurF ligase, and possible sequence of the chlamydial peptidoglycan pentapeptide stem. Arch Microbiol (2012) 0.96
In vitro studies indicate a high resistance potential for the lantibiotic nisin in Staphylococcus aureus and define a genetic basis for nisin resistance. Antimicrob Agents Chemother (2011) 0.95
The silver cation (Ag+): antistaphylococcal activity, mode of action and resistance studies. J Antimicrob Chemother (2012) 0.95
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem (2007) 0.95
XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity. J Antimicrob Chemother (2009) 0.95
Staphylococcus aureus biofilms promote horizontal transfer of antibiotic resistance. Antimicrob Agents Chemother (2013) 0.93
Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem (2009) 0.92
Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother (2008) 0.90
Escherichia coli mutators present an enhanced risk for emergence of antibiotic resistance during urinary tract infections. Antimicrob Agents Chemother (2004) 0.89
Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB). Bioorg Med Chem Lett (2009) 0.87
Furanyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymerase. Antimicrob Agents Chemother (2010) 0.87
Assessment of a microplate method for determining the post-antibiotic effect in Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother (2004) 0.86
Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl). Bioorg Med Chem Lett (2007) 0.86
Structure-based design of anti-infectives. Ann N Y Acad Sci (2010) 0.86
Intrinsic novobiocin resistance in Staphylococcus saprophyticus. Antimicrob Agents Chemother (2007) 0.85
Deletion of the multiple-drug efflux pump AcrAB in Escherichia coli prolongs the postantibiotic effect. Antimicrob Agents Chemother (2005) 0.85
The first de novo-designed antagonists of the human NK(2) receptor. J Med Chem (2005) 0.85
Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. Bioorg Med Chem (2009) 0.85
Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases. J Med Chem (2012) 0.84
Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J Antimicrob Chemother (2012) 0.83
Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium (2011) 0.83
Zeocin resistance suppresses mutation in hypermutable Escherichia coli. Microbiology (2003) 0.83
Activity of and development of resistance to corallopyronin A, an inhibitor of RNA polymerase. Antimicrob Agents Chemother (2011) 0.82
Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity. Bioorg Med Chem Lett (2014) 0.82
Adenosine tetraphosphoadenosine drives a continuous ATP-release assay for aminoacyl-tRNA synthetases and other adenylate-forming enzymes. ACS Chem Biol (2013) 0.81
Population diversification in Staphylococcus aureus biofilms may promote dissemination and persistence. PLoS One (2013) 0.81
Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175). J Antimicrob Chemother (2005) 0.81
6-Arylpyrido[2,3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial D-alanine:D-alanine ligase. PLoS One (2012) 0.80
Adsorption and self-assembly of peptides on mica substrates. Angew Chem Int Ed Engl (2005) 0.80
Structure-activity relationships of new cyanothiophene inhibitors of the essential peptidoglycan biosynthesis enzyme MurF. Eur J Med Chem (2013) 0.80
Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother (2003) 0.80
2-Aminotetralones: novel inhibitors of MurA and MurZ. Bioorg Med Chem Lett (2008) 0.80
Further characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studies. Antimicrob Agents Chemother (2011) 0.80
A study of the effects of substituents on the selectivity of the binding of N-arylaminomethylene malonate inhibitors to DHODH. Bioorg Med Chem Lett (2009) 0.79
"tet(U)" is not a tetracycline resistance determinant. Antimicrob Agents Chemother (2012) 0.79
A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew Chem Int Ed Engl (2005) 0.78
Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening. J Med Chem (2008) 0.78
Small molecule inhibitors of peptidoglycan synthesis targeting the lipid II precursor. Biochem Pharmacol (2011) 0.78
Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg Med Chem Lett (2009) 0.78
Computational methods to identify new antibacterial targets. Chem Biol Drug Des (2015) 0.78
Mutagenesis mapping of the protein-protein interaction underlying FusB-type fusidic acid resistance. Antimicrob Agents Chemother (2013) 0.77
Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase. Bioorg Med Chem (2011) 0.77
Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp. ChemMedChem (2012) 0.77
Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD. Bioorg Med Chem Lett (2003) 0.77